AKORN INC Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2018-04-27: Study NCT03522441; Company role Lead sponsor; Phase Phase 3; Status Completed.
- 2015-10: Study NCT02758327; Company role Collaborator; Phase Phase 4; Status Completed.
- 2015-08: Study NCT02624843; Company role Lead sponsor; Phase Phase 3; Status Completed.
- 2015-06: Study NCT02913521; Company role Lead sponsor; Phase Phase 3; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2018-04-27 | NCT03522441 Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris | Lead sponsor | Phase 3 | Completed Results posted | Acne Vulgaris | 1,125 | 2019-04-22 |
| 2015-10 | NCT02758327 Evaluation of Tear Osmolarity Over Time With Sustained Use of Thera Tears Lubricating Drops | Collaborator Lead: Koffler Vision Group | Phase 4 | Completed | Dry Eye Syndrome | 14 | 2016-03 |
| 2015-08 | NCT02624843 Bioequivalence Study for Benzyl Alcohol Lotion 5%. | Lead sponsor | Phase 3 | Completed Results posted | Head Lice | 239 | 2015-11 |
| 2015-06 | NCT02913521 Bioequivalence Study With Clinical Endpoint for Diclofenac Sodium Topical Gel 1% | Lead sponsor | Phase 3 | Completed Results posted | Osteoarthritis, Knee | 934 | 2016-06 |
| 2015-05 | NCT02423148 Pilot Study of Novel Fluorescence Endoscopic Device for Sentinel Lymph Node Mapping in Lung Cancer | Collaborator Lead: Dana-Farber Cancer Institute | Not applicable | Withdrawn | Lung Cancer | 0 | 2016-11-03 |
| 2012-03 | NCT01561521 An Evaluation of the Onset and Duration of Action of AKF-1 Ophthalmic Solution in Treating Acute Allergic Conjunctivitis | Lead sponsor | Phase 3 | Completed | Allergic Conjunctivitis | 90 | 2012-04 |